A pilot study evaluating interleukin-2-activated hematopoietic stem cell transplantation for hematologic malignancies

Area of Science:

• Oncology
• Immunotherapy
• Hematology

Background:

• Autologous hematopoietic stem cells (HSC) cultured with IL-2 generate cytotoxic effector cells.
• These cells, infused with IL-2, may induce a graft-versus-tumor (GvT) effect.
• This pilot study investigates this approach in patients with hematologic malignancies.

Purpose of the Study:

• To evaluate the safety and efficacy of infusing IL-2 activated autologous HSC.
• To assess the potential for a graft-versus-tumor (GvT) effect.
• To determine the impact on engraftment times and overall survival.

Main Methods:

• Sixteen patients with NHL, AML, MM, or HD received conditioning chemotherapy (busulfan/cyclophosphamide or cyclophosphamide/TBI).
• Autologous HSC were cultured with IL-2 for 24 hours before reinfusion.
• Subcutaneous IL-2 administration followed engraftment for 1-4 weeks.

Main Results:

• Median neutrophil engraftment was day 13.1; median platelet engraftment was day 19.3, with delayed engraftment in 3 patients.
• One patient experienced fatal cardiac arrhythmia; 5 developed transient skin rashes consistent with GvHD.
• At a median of 17 months, 9 patients were alive, with 6 disease-free.

Conclusions:

• The therapy demonstrated mild to moderate toxicities and a potential delay in platelet engraftment.
• Further trials are needed to optimize IL-2 dosage and duration and confirm survival benefits.
• Ongoing laboratory studies are assessing autologous GvHD and GvT effects.